Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Daiichi Sankyo Company, Limited    4568   JP3475350009

DAIICHI SANKYO COMPANY, LIMITED

(4568)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations
Communiqués de presse de la société DAIICHI SANKYO COMPANY, LI
01/27DAIICHI SANKYO : Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy ..
BU
01/07DAIICHI SANKYO : ENHERTU Now Available in U.S. for HER2 Positive Unresectable or..
AQ
2019DAIICHI SANKYO : AstraZeneca - Enhertu approved in the US for HER2-positive unre..
AQ
2019DAIICHI SANKYO : ENHERTU Approved in the U.S. for HER2 Positive Unresectable or ..
AQ
2019DAIICHI SANKYO : Enhertu (trastuzumab deruxtecan) approved in the US for HER2-po..
AQ
2019DAIICHI SANKYO : Launches Antitumor Agent Bevacizumab Biosimilar for Intravenous..
AQ
2019ASTRAZENECA : Trastuzumab deruxtecan achieved a tumour response rate of 60.9% in..
AQ
2019DAIICHI SANKYO : Announces Positive Results from ESAX-DN Phase 3 study in Japan ..
AQ
2019DAIICHI SANKYO : Files Declaratory Judgement Action Related to its Proprietary A..
AQ
2019DAIICHI SANKYO : Announces Transfer from Astellas Pharma of Three Products in As..
AQ
2019Mitsubishi Tanabe Pharma and Daiichi Sankyo announce alliance for ALS treatme..
AQ
2019DAIICHI SANKYO : Announces Launch of Oxycodone Extended Release Tablets NX 'Daii..
AQ
2019Influenza Vaccines Market is Expected to Surpass USD 6 billion by 2025 | Key ..
AQ
2019MCKESSON : TURALIO FDA Approved Treatment of TGCT, Available at Biologics by McK..
AQ
2019DAIICHI SANKYO : FDA Approves Daiichi Sankyo's TURALIO for the Treatment of Sele..
AQ
2019GENERAL ELECTRIC : Daiichi Sankyo to transfer marketing authorization rights for..
AQ
2019DAIICHI SANKYO : Provides Update on FDA Review of Quizartinib for the Treatment ..
AQ
2019DAIICHI SANKYO : VANFLYTA Receives Approval in Japan for the Treatment of Relaps..
AQ
2019DAIICHI SANKYO : Integral Molecular reaches milestone in I-O target discovery co..
AQ
2019DAIICHI SANKYO : Announcement Regarding Recent Media Reports
AQ
2019DAIICHI SANKYO : Announces Update to H5N1 Influenza Vaccine National Project
AQ
2019DAIICHI SANKYO : FDA advisory panel votes against Daiichi Sankyos quizartinib
AQ
2019DAIICHI SANKYO : FDA Oncologic Drugs Advisory Committee Votes in Favor of Daiich..
AQ
2019DAIICHI SANKYO : Precision NanoSystems Signs License Agreement with Daiichi Sank..
AQ
2019DAIICHI SANKYO : FDA questions credibility of Daiichi data ahead of AdComm
AQ
2019EXELIXIS' : Collaborator Daiichi Sankyo Launches MINNEBRO Tablets in Japan
AQ
2019DAIICHI SANKYO : Launches 'MINNEBRO Tablets' in Japan
AQ
2019DAIICHI SANKYO : AstraZeneca - Fam trastuzumab deruxtecan demonstrated clinicall..
AQ
2019ASTRAZENECA : Trastuzumab deruxtecan demonstrated clinically
AQ
2019DAIICHI SANKYO : Announcement Regarding Vaccine Quality Testing Methods
AQ
2019ZYMEWORKS : Daiichi Sankyo Selects Lead Candidate Built on Zymeworks' Azymetric ..
AQ
2019DAIICHI SANKYO : Announces Regarding Vaccine Quality Testing Methods
PU
2019DAIICHI SANKYO : Announces the Sale of Its Nihonbashi Building in Japan
PU
2019DAIICHI SANKYO : LifeArc licenses discovery programme to Daiichi Sankyo
AQ
2019DAIICHI SANKYO : Launches 'Tarlige Tablets' for Pain Treatment in Japan
AQ
2019DAIICHI SANKYO : Launches “Tarlige® Tablets” for Pain Treatment in J..
PU
2019DAIICHI SANKYO : Supreme Court reserves order on Daiichi Sankyo plea
AQ
2019DAIICHI SANKYO : EZH1/2 Dual Inhibitor Valemetostat (DS-3201) Receives SAKIGAKE ..
PU
2019DAIICHI : s Xospata rival pushed back by FDA as it combs through new data
AQ
2019DAIICHI SANKYO : SC to jail ex-Ranbaxy promoters if found guilty of not paying D..
AQ
2019DAIICHI SANKYO : Provides Update on Ongoing FDA Review for Quizartinib for Treat..
PU
2019DAIICHI SANKYO : EMA Validates Daiichi Sankyo's Marketing Authorization Applicat..
PU
2019DAIICHI SANKYO : Pharma taps new CEO just as it unveils a big tie-up with AstraZ..
AQ
2019DAIICHI SANKYO : AstraZeneca in cancer deal with Daiichi Sankyo
AQ
2019ASTRAZENECA : AZ and Daiichi Sankyo enter collaboration in novel
AQ
2019DAIICHI SANKYO : to tie up with AstraZeneca on new cancer drug
AQ
2019DAIICHI SANKYO : Announces Chief Executive Officer (CEO) Change
PU
2019DAIICHI SANKYO : and AstraZeneca Announce Global Development and Commercializati..
PU
2019DAIICHI SANKYO : Confirms Plans to Accelerate BLA Submission to U.S. FDA for Tra..
PU
2019DAIICHI SANKYO : Initiates Phase 3 Trial of Mirogabalin in Asian Post-spinal Cor..
PU
2019DAIICHI SANKYO : Anti-epilepsy Drug VIMPAT for I.V. infusion 200mg Launched in J..
AQ
2019DAIICHI SANKYO : Data from the Non-interventional EMIT-AF/VTE Study Shows Low Th..
AQ
2019DAIICHI SANKYO : Presents Positive Results of the First Randomized, Controlled T..
AQ
2019DAIICHI SANKYO : Presents Positive Results of the First Randomized, Controlled T..
PU
2019DAIICHI SANKYO : Anti-epilepsy Drug VIMPAT Dry syrup 10% Launched in Japan
AQ
2019DAIICHI SANKYO : Anti-epilepsy Drug VIMPAT® Dry syrup 10% Launched in Japan
PU
2019DAIICHI SANKYO : Announces Organizational Restructuring Effective April 1, 2019 ..
PU
2019DAIICHI SANKYO : Appoints New Group Corporate Officers
PU
2019DAIICHI SANKYO : FDA Grants Priority Review for Daiichi Sankyo's New Drug Applic..
PU
2019DAIICHI SANKYO : Announces Transfer of Daiichi Sankyo Propharma Takatsuki Plant ..
PU
2019DAIICHI SANKYO : Initiates Pivotal Phase 3 Trial of Trastuzumab Deruxtecan (DS-8..
PU
2019DAIICHI SANKYO : Mitsubishi UFJ Capital and Tokyo Institute of Technology Announ..
PU
2019DAIICHI SANKYO : Announces Marketing Approval in Japan of “Tarlige® Tablet..
PU
2019DAIICHI SANKYO : Announces Approval of MINNEBRO(TM) Tablets for the Treatment of..
PU
2019DAIICHI SANKYO : Pediatric Dosage and Administration Approved for Anti-epileptic..
PU
2019DAIICHI SANKYO : Europe Enters into European Licensing Agreement with Esperion f..
PU
2018DAIICHI SANKYO : Announces Date for Dissolution of Japan Vaccine and Measures fo..
PU
2018DAIICHI SANKYO : Initiates First Novel-Novel Combination Study of Two Investigat..
PU
2018DAIICHI SANKYO : Out-Licenses ROS1/NTRK Inhibitor DS-6051 to AnHeart Therapeutic..
PU
2018DAIICHI SANKYO : and Sarah Cannon Research Institute Launch Strategic Collaborat..
PU
2018DAIICHI SANKYO : Presents Updated Phase 1 Results of Trastuzumab Deruxtecan (DS-..
PU
2018DAIICHI SANKYO : Presents Updated Phase 1 Data for U3-1402 in Patients with HER3..
PU
2018DAIICHI SANKYO : Announces Reorganization Scheme for Kitasato Daiichi Sankyo Vac..
PU
2018DAIICHI SANKYO : Launches Antitumor Agent Trastuzumab Biosimilar for Intravenous..
PU
2018DAIICHI SANKYO : and Roche to Collaborate on New HER2 Low Companion Diagnostic T..
PU
1  2  3  4  5  6Next
Upcoming event on DAIICHI SANKYO COMPANY, LI